NOVEL 1-PHENYLCYCLOALKANECARBOXYLIC ACID-DERIVATIVES ARE POTENT AND SELECTIVE SIGMA(1) LIGANDS

被引:25
作者
CALDERON, SN
IZENWASSER, S
HELLER, B
GUTKIND, JS
MATTSON, MV
SU, TP
NEWMAN, AH
机构
[1] NIDA,INTRAMURAL RES PROGRAM,PSYCHOBIOL SECT,DRUG DEV GRP,BALTIMORE,MD 21224
[2] NIDA,INTRAMURAL RES PROGRAM,PHARMACOL SECT,NEUROCHEM UNIT,BALTIMORE,MD 21224
[3] NIDR,LCDO,MOLEC SIGNALING UNIT,BETHESDA,MD 20892
[4] NIDDKD,MED CHEM LAB,BETHESDA,MD 20892
关键词
D O I
10.1021/jm00041a006
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Carbetapentane (1, 2-[2-(diethylamino)ethoxy]ethyl 1-phenyl-1-cyclopentanecarboxylate) binds with high affinity to sigma sites and is a potent antitussive, anticonvulsant, and spasmolytic agent. However, carbetapentane interacts at muscarinic binding sites as well, and it is not clear whether either of these receptor systems is involved in the mechanism(s) of action(s) of this drug. In an attempt to determine whether these psychoactivities can be attributed to interaction at sigma sites, a series of carbetapentane analogs were prepared. Phenyl ring substitution; contraction, expansion, and replacement with a methyl group of the cyclopentyl ring; replacement of the carboxylate function with an amide, methyl ether, and methylamine; and replacement of the N,N-diethyl substituent with a morpholino or piperidino moiety were investigated. All of these novel analogs were evaluated for binding to sigma(1) and sigma(2) sites, and comparison of binding at muscarinic m(1) and m(2) and PCP (1-(1-phenylcyclohexyl)piperidine) receptors was performed. Ah of the compounds were selective for or over oz sites, with the three most selective analogs being compounds 34 (65-fold), 35 (78-fold), and 39 (51-fold). None of the compounds were active at PCP sites, and chemical modification including (1) replacing the ester function, (2) replacing the cyclopentyl ring with a smaller ring system (cyclopropyl) or a methyl group, and (3) replacing the diethylamino moiety with a morpholino group resulted in >220-fold selectivity over muscarinic receptor binding. Therefore, several of these novel compounds are potent, sigma(1)-selective ligands which can now be investigated as potential antitussive, anticonvulsant, and antiischemic agents. These studies may reveal whether or sites play a role in the pharmacological actions of these drugs.
引用
收藏
页码:2285 / 2291
页数:7
相关论文
共 35 条
[11]   NOVEL PIPERIDINE SIGMA RECEPTOR LIGANDS AS POTENTIAL ANTIPSYCHOTIC-DRUGS [J].
GILLIGAN, PJ ;
CAIN, GA ;
CHRISTOS, TE ;
COOK, L ;
DRUMMOND, S ;
JOHNSON, AL ;
KERGAYE, AA ;
MCELROY, JF ;
ROHRBACH, KW ;
SCHMIDT, WK ;
TAM, SW .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (23) :4344-4361
[12]   IDENTIFICATION AND EXPLOITATION OF THE SIGMA-OPIATE PHARMACOPHORE [J].
GLENNON, RA ;
SMITH, JD ;
ISMAIEL, AM ;
ELASHMAWY, M ;
BATTAGLIA, G ;
FISCHER, JB .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (03) :1094-1098
[13]   BINDING OF SUBSTITUTED AND CONFORMATIONALLY RESTRICTED DERIVATIVES OF N-(3-PHENYL-N-PROPYL)-1-PHENYL-2-AMINOPROPANE AT SIGMA-RECEPTORS [J].
GLENNON, RA ;
ISMAIEL, AM ;
SMITH, JD ;
YOUSIF, M ;
ELASHMAWY, M ;
HERNDON, JL ;
FISCHER, JB ;
HOWIE, KJB ;
SERVER, AC .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (06) :1855-1859
[14]  
GUND TM, 1992, MULTIPLE SIGMA PCP R, P53
[15]   MUSCARINIC ACETYLCHOLINE-RECEPTOR SUBTYPES AS AGONIST-DEPENDENT ONCOGENES [J].
GUTKIND, JS ;
NOVOTNY, EA ;
BRANN, MR ;
ROBBINS, KC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :4703-4707
[16]   SYNTHESIS AND BINDING CHARACTERISTICS OF POTENTIAL SPECT IMAGING AGENTS FOR SIGMA-1 AND SIGMA-2 BINDING-SITES [J].
HE, XS ;
BOWEN, WD ;
LEE, KS ;
WILLIAMS, W ;
WEINBERGER, DR ;
DECOSTA, BR .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (05) :566-571
[17]   M1 MUSCARINIC ANTAGONISTS INTERACT WITH SIGMA-RECOGNITION SITES [J].
HUDKINS, RL ;
DEHAVENHUDKINS, DL .
LIFE SCIENCES, 1991, 49 (17) :1229-1235
[18]  
KAISER C, 1991, NEUROTRANSMISSIONS, V7, P1
[19]   QUANTITATIVE CONFORMATIONAL-ANALYSES PREDICT DISTINCT RECEPTOR-SITES FOR PCP-LIKE AND SIGMA-DRUGS [J].
MANALLACK, DT ;
BEART, PM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 144 (02) :231-235
[20]  
MANALLACK DT, 1988, MOL PHARMACOL, V34, P863